Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plaque reduction neutralization test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Plaque reduction neutralization test. Displaying page 1 of 1.
    EudraCT Number: 2019-000993-44 Sponsor Protocol Number: CYD63 Start Date*: 2019-06-13
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002771-14 Sponsor Protocol Number: IC51-310 Start Date*: 2007-10-24
    Sponsor Name:Intercell AG
    Full Title: COMPARISON OF THREE COMMERCIAL BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51. DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003136-23 Sponsor Protocol Number: CYD66 Start Date*: 2020-02-12
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004037-26 Sponsor Protocol Number: MV-CHIK-202 Start Date*: 2017-04-11
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Double blinded, randomized, Priorix®- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability ...
    Medical condition: The MV-CHIK vaccine candidate is developed to prevent infection with the mosquito borne Chikungunya Virus. This Phase 2 trial is designed to investigate the immunogenicity, safety and tolerability ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001658-14 Sponsor Protocol Number: V920-012 Start Date*: 2015-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.
    Full Title: A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lot Doses and a High Dose of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Ad...
    Medical condition: Prevention of Ebola infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10014074 Ebola virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000801-61 Sponsor Protocol Number: ITM201901 Start Date*: 2019-05-09
    Sponsor Name:Institute of Tropical Medicine Antwerp
    Full Title: Toward an optimal accelerated Tick-Borne Encephalitis (TBE) vaccination schedule for the last-minute traveler
    Medical condition: Thick-Borne Encephalitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005509-28 Sponsor Protocol Number: 901452-CT-21-001 Start Date*: 2022-02-10
    Sponsor Name:Akston Biosciences Corporation
    Full Title: Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002793-64 Sponsor Protocol Number: IC51-311 Start Date*: 2007-10-24
    Sponsor Name:Intercell AG
    Full Title: EFFECT OF A BOOSTER DOSE OF THE JAPANESE ENCEPHALITIS VACCINE IC51 ON LONG TERM IMMUNOGENICITY. AN UNCONTROLLED, OPEN-LABEL PHASE 3 STUDY.
    Medical condition: Japanese Encephalitis (JE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003135-36 Sponsor Protocol Number: CYD67 Start Date*: 2019-10-31
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005997-82 Sponsor Protocol Number: 900452-CT-20-001 Start Date*: 2021-03-12
    Sponsor Name:UMCG
    Full Title: Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study (ACT-study)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001781-14 Sponsor Protocol Number: POX-MVA-005 Start Date*: 2006-04-11
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine i...
    Medical condition: Healthy subjects - prevention of smallpox infection
    Disease: Version SOC Term Classification Code Term Level
    8.0 10041197 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000994-22 Sponsor Protocol Number: CYD71 Start Date*: 2019-06-13
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005137-37 Sponsor Protocol Number: POX-MVA-035 Start Date*: 2013-07-15
    Sponsor Name:Bavarian Nordic A/S
    Full Title: Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN® smallpox vaccine in children from birth to less than 12 years of age
    Medical condition: Prevention of smallpox infection in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10041197 Smallpox PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004501-30 Sponsor Protocol Number: V181-003 Start Date*: 2022-06-14
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [live, attenuated]) ...
    Medical condition: Prevention of dengue disease in toddlers, children, and adults in endemic areas, as well as travelers to endemic areas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10012309 Dengue LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-004905-26 Sponsor Protocol Number: 115649 Start Date*: 2012-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s MMR vaccine when both are given on a 2-dose schedule to...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10028257 Mumps PT
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    17.0 10021881 - Infections and infestations 10039252 Rubella PT
    17.0 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015595-10 Sponsor Protocol Number: IC51-322 Start Date*: 2010-03-23
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®, JESPECT®) IN A PEDIATRIC POPULATION IN NON‐ENDEMIC COUNTRIES. UNCONTROLLED, OPEN‐LABEL PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018630-52 Sponsor Protocol Number: IC51-315 Start Date*: 2010-05-27
    Sponsor Name:Intercell AG
    Full Title: AN OPEN-LABEL, UNCONTROLLED PHASE 4 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS (JE) VACCINE IXIARO® (IC51) IN AN ELDERLY POPULATION
    Medical condition: IXIARO® is used to protect adults against Japanese encephalitis (JE). JE can be fatal or lead to long-term disability. Vaccination with Ixiaro should be considered for people who are at risk of exp...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10014596 Encephalitis Japanese B LLT
    12.1 10023119 Japanese B encephalitis LLT
    12.1 10023120 Japanese B viral encephalitis LLT
    12.1 10023122 Japanese B virus encephalitis LLT
    12.1 10023123 Japanese encephalitis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006161-18 Sponsor Protocol Number: 115650 Start Date*: 2014-09-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc....
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases in healthy children, 12 to 15 months of age)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10069547 Mumps immunization LLT
    18.0 100000004862 10039276 Rubella with unspecified complications LLT
    18.0 100000004862 10039274 Rubella with other specified complication LLT
    18.0 100000004865 10069545 Measles immunization LLT
    18.0 100000004865 10069564 Rubella immunization LLT
    18.0 100000004862 10028276 Mumps with unspecified complication LLT
    18.0 100000004862 10027015 Measles like illness LLT
    18.0 100000004862 10028275 Mumps with other specified complications LLT
    18.0 100000004862 10027021 Measles without mention of complication LLT
    18.0 100000004862 10027020 Measles with unspecified complication LLT
    18.0 100000004858 10027022 Measles-like rash LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-022265-10 Sponsor Protocol Number: IC51-325 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: LONG TERM IMMUNITY AND SAFETY WITH OR WITHOUT A BOOSTER DOSE FOLLOWING PRIMARY VACCINATION WITH THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION IN A JEV-ENDEMIC COUNTRY. ...
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015588-15 Sponsor Protocol Number: IC51-323 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION. OPEN LABEL, RANDOMIZED, ACTIVE CONTROLLED, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:41:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA